Consent given pursuant to sections 14 and 14A for the supply and importation of the Therapeutic Goods specified subject to conditions specified - Vedafil by Alphapharm Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and importation of therapeutic goods in Australia, ensuring that these products are safe, of high quality, and have appropriate labelling and advertising. This Act addresses the gap in regulatory oversight for therapeutic goods, aiming to protect public health by ensuring that such goods meet specific standards before they are made available to consumers. Enacted by the Australian Parliament, the policy objective of the Therapeutic Goods Act 1989 is to safeguard the health of the Australian population by regulating therapeutic goods in a manner that balances public health protection with enabling access to beneficial products. In specific instances, the Act allows for certain exemptions or consents, such as the one issued on July 28, 2014, by the delegate of the Secretary of the Department of Health for Alphapharm Pty Limited, permitting the supply of sildenafil products that do not fully comply with labelling requirements, subject to conditions designed to mitigate any potential risks to public health.

Scope and Application

The Therapeutic Goods Act 1989 applies to various entities, including manufacturers, suppliers, and importers of therapeutic goods in Australia. This legislation provides a framework for regulating therapeutic goods to ensure their safety, quality, and efficacy. The Act applies to a broad range of therapeutic goods, including medicines, medical devices, and blood products. It applies to the entire Commonwealth of Australia, encompassing all states and territories, establishing a uniform regulatory environment across the nation. In this specific instance, the Act facilitates the importation and supply of certain batches of sildenafil under particular conditions, as detailed in the Gazette. This consent is granted under the authority of the Secretary of the Department of Health, who has the power to make decisions under subsection 14 and 14A of the Act. The consent granted to Alphapharm Pty Limited allows for the importation and supply of specific batches of sildenafil that do not fully comply with certain labelling requirements, provided that a Dear Pharmacist letter is included with the product. This letter informs pharmacists of the specific circumstances and provides instructions to patients. The consent is limited to particular batches with specified quantities and expiry dates, ensuring the controlled distribution of the therapeutic goods in question.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) contains various sections that govern the regulation of therapeutic goods in Australia. Sections 14 and 14A of the Act pertain to consents for the importation and supply of therapeutic goods that do not fully comply with the Therapeutic Goods Regulations. In this instance, the Secretary of the Department of Health has granted Alphapharm Pty Limited consent under these sections to supply specific batches of sildenafil products that do not meet certain labelling requirements (Section 14(1), 14A(1)). Specifically, the foil labels on the sildenafil (as citrate) (VEDAFIL) 25 mg and 50 mg film-coated tablet blister packs do not contain the name or registered trade mark of the sponsor or supplier, which contravenes the Therapeutic Goods Order No. 69 (Section 3(13)(a)). This consent is limited to particular batches of the product, with specific quantities and expiry dates (Section 14(1), 14A(1)). The consent issued under Section 15 of the Act imposes certain obligations on Alphapharm Pty Limited. Firstly, they must ensure that a Dear Pharmacist letter, dated July 23, 2014, is supplied alongside the affected batches. This letter explains the circumstances that led to the consent and reminds patients to keep the blister platforms in the outer carton until immediately before taking a dose (Section 15(1)). The letter is intended to inform healthcare professionals about the specific issue with the product and to provide instructions on how to handle it appropriately. This is crucial to mitigate any potential risks associated with the non-compliant labelling. Failure to comply with the conditions set out in the consent may result in legal consequences. While the Therapeutic Goods Act 1989 does not explicitly detail the penalties for non-compliance with consent conditions, breaches of other provisions of the Act can result in significant fines and imprisonment. For example, under Section 28 of the Act, an individual can be fined up to $66,000 or five years' imprisonment, or both, for supplying therapeutic goods that do not comply with the Act. Similarly, under Section 32, an individual can be fined up to $1,100,000 or ten years' imprisonment, or both, for contravening a prohibition or restriction. These penalties underscore the importance of adhering to the conditions of the consent to avoid severe legal repercussions.